KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Q3 2025 value amounting to $44.4 million.

  • Alnylam Pharmaceuticals' Interest Expenses rose 2915.41% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.3 million, marking a year-over-year increase of 2088.73%. This contributed to the annual value of $141.9 million for FY2024, which is 1702.43% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Interest Expenses is $44.4 million, which was up 2915.41% from $40.2 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Interest Expenses ranged from a high of $44.4 million in Q3 2025 and a low of $29.0 million during Q1 2023
  • Its 5-year average for Interest Expenses is $36.1 million, with a median of $35.3 million in 2024.
  • In the last 5 years, Alnylam Pharmaceuticals' Interest Expenses surged by 4017.61% in 2021 and then tumbled by 3164.86% in 2023.
  • Alnylam Pharmaceuticals' Interest Expenses (Quarter) stood at $36.8 million in 2021, then decreased by 18.75% to $29.9 million in 2022, then increased by 4.76% to $31.3 million in 2023, then rose by 24.36% to $39.0 million in 2024, then increased by 13.93% to $44.4 million in 2025.
  • Its last three reported values are $44.4 million in Q3 2025, $40.2 million for Q2 2025, and $38.6 million during Q1 2025.